Ghrelin, insulin-like growth factor I and adipocytokines concentrations in born small for gestational age prepubertal children after the catch-up growth

Stawerska, Renata; Szałapska, Małgorzata; Hilczer, Maciej; Lewiński, Andrzej

doi:10.1515/jpem-2015-0463

Cited by 16 publications

(13 citation statements)

References 40 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although nutrient intake may be lower in very young children born SGA than AGA peers, intake increased with age during childhood [41]. An increased production of ghrelin and IGF-I and the development of insulin resistance could be an adaptive mechanism to achieve normal growth in SGA children [42].…”

Section: Body Compositionmentioning

confidence: 99%

What is the evidence for beneficial effects of growth hormone treatment beyond height in short children born small for gestational age? A review of published literature

Darendelıler

Kandemir

Harris

et al. 2019

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

BackgroundAn increasing body of evidence supports the view that both an adverse intrauterine milieu and rapid postnatal weight gain in children born small for gestational age (SGA) contribute towards the risk for the development of chronic diseases in adult life.ContentThe aim of this review was to identify and summarize the published evidence on metabolic and cardiovascular risk, as well as risk of impaired cardiac function, intellectual capacity, quality of life, pubertal development and bone strength among children born SGA. The review will then address whether growth hormone (GH) therapy, commonly prescribed to reduce the height deficit in children born SGA who do not catch up in height, increases or decreases these risks over time.SummaryOverall, there are limited data in support of a modest beneficial effect of GH therapy on the adverse metabolic and cardiovascular risk observed in short children born SGA. Evidence to support a positive effect of GH on bone strength and psychosocial outcomes is less convincing.OutlookFurther evaluation into the clinical relevance of any potential long-term benefits of GH therapy on metabolic and cardiovascular endpoints is warranted.

show abstract

Section: Body Compositionmentioning

confidence: 99%

What is the evidence for beneficial effects of growth hormone treatment beyond height in short children born small for gestational age? A review of published literature

Darendelıler

Kandemir

Harris

et al. 2019

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…In our earlier work [43] we found that in prepubertal SGA children with catch-up, higher ghrelin and higher IGF-I concentration were observed than in SGA children without catch-up. Thus, we also analysed the differences in the concentrations of these hormones, depending on the genotypes.…”

Section: Discussionmentioning

confidence: 66%

Wpływ występowania allelu klasy III VNTR genu INS na parametry auksologiczne, stężenie glukozy, insuliny, lipidów i adipocytokin u przeddojrzewaniowych dzieci urodzonych z niską masą ciała

Stawerska

Szałapska

Borowiec

et al. 2016

Endokrynologia Polska

Self Cite

View full text Add to dashboard Cite

Introduction:The insulin gene variable number of tandem repeats (INS VNTR) class III allele has been implicated in lower birth weight, obesity, and insulin resistance. We assessed its influence on birth weight in the Polish population and on the current body mass and metabolic profile in prepubertal children born small for gestational age (SGA). Material and methods: DNA for genotyping of INS VNTR was available for 123 subjects born SGA and 132 born appropriate for gestational age (AGA). We identified two alleles: class I and class III. Next, in 112 prepubertal (aged: 6.8 ± 1.38 years) SGA children, the auxological measurements, fasting serum C-peptide, triglycerides, cholesterol, ghrelin, leptin, adiponectin, resistin, cortisol, and insulin-like growth factor type I (IGF-I) concentrations, as well as glucose and insulin during oral glucose tolerance test (OGTT), were assessed and insulin resistance indices were calculated. The results were analysed depending on INS VNTR variants. Results: The occurrence of individual INS VNTR variants were similar in the SGA and AGA groups. In prepubertal SGA children, we did not observe any statistical differences as regards birth weight, body mass, lipids, or adipocytokine concentrations among I/I, I/III, and III/III class groups. The concentration of insulin in 120' of OGTT was significantly higher in class III homozygous than in class I homozygous individuals. Conclusions: Variant INS VNTR class III was shown not to be associated in any essential way with birth weight in the Polish population. Among prepubertal SGA children, the presence of INS VNTR class III is related to higher insulin secretion during OGTT. (Endokrynol Pol 2016; 67 (6): 585-591)

show abstract

“…Significantly lower adiponectin concentrations in SGA children, even with catch-up growth, compared with AGA children, were also noted [50]. A fat cell hypertrophy, paradoxically associated with decreased adiponectin expression in adipocytes, was implicated as a mechanism [33].…”

Section: Discussionmentioning

confidence: 93%

“…In obese children and adolescents, hypoadiponectinemia and hyperleptinemia, as well as higher values of resistin were well correlated with an atherogenic lipid profile and markers of IR [65,66]. The majority of these correlations have also been documented in term SGA children [50,67]. However, the literature on the role of adipokines in regulating lipid metabolism and/or insulin sensibility in preterm children is limited [20].…”

Section: Discussionmentioning

confidence: 99%

Plasma Adipokines Profile in Prepubertal Children with a History of Prematurity or Extrauterine Growth Restriction

et al. 2020

View full text Add to dashboard Cite

Adipose tissue programming could be developed in very preterm infants with extrauterine growth restriction (EUGR), with an adverse impact on long-term metabolic status, as was studied in intrauterine growth restriction patterns. The aim of this cohort study was to evaluate the difference in levels of plasma adipokines in children with a history of EUGR. A total of 211 school age prepubertal children were examined: 38 with a history of prematurity and EUGR (EUGR), 50 with a history of prematurity with adequate growth (PREM), and 123 healthy children born at term. Anthropometric parameters, blood pressure, metabolic markers and adipokines (adiponectin, resistin, leptin) were measured. Children with a history of EUGR showed lower values of adiponectin (μg/mL) compared with the other two groups: (EUGR: 10.6 vs. PREM: 17.7, p < 0.001; vs. CONTROL: 25.7, p = 0.004) and higher levels of resistin (ng/mL) (EUGR: 19.2 vs. PREM: 16.3, p =0.007; vs. CONTROL: 7.1, p < 0.001. The PREM group showed the highest values of leptin (ng/mL), compared with the others: PREM: 4.9 vs. EUGR: 2.1, p = 0.048; vs. CONTROL: 3.2, p = 0.029). In conclusion, EUGR in premature children could lead to a distinctive adipokines profile, likely associated with an early programming of the adipose tissue, and likely to increase the risk of adverse health outcomes later in life.

show abstract

Ghrelin, insulin-like growth factor I and adipocytokines concentrations in born small for gestational age prepubertal children after the catch-up growth

Cited by 16 publications

References 40 publications

What is the evidence for beneficial effects of growth hormone treatment beyond height in short children born small for gestational age? A review of published literature

What is the evidence for beneficial effects of growth hormone treatment beyond height in short children born small for gestational age? A review of published literature

Wpływ występowania allelu klasy III VNTR genu INS na parametry auksologiczne, stężenie glukozy, insuliny, lipidów i adipocytokin u przeddojrzewaniowych dzieci urodzonych z niską masą ciała

Plasma Adipokines Profile in Prepubertal Children with a History of Prematurity or Extrauterine Growth Restriction

Contact Info

Product

Resources

About